Baseline characteristics of clients in the trial, by study arm

Characteristic	Total	Early Implementers (Phase 1)	Late Implementers (Phase 2)	p-value*
	N (%)	N (%)	N (%)	
	960 (100.0%)	531 (55.3%)	429 (44.7%)	
Age Group				
Under 25 years	56 (5.8%)	24 (4.5%)	32 (7.5%)	
25 – 44 years	399 (41.6%)	194 (36.5%)	205 (47.8%)	0.0002*
45 – 54 years	238 (24.8%)	148 (27.9%)	90 (21.0%)	
55 years and older	267 (27.8%)	165 (31.1%)	102 (23.8%)	
Gender Identity				
Cisgender man or boy	626 (65.2%)	331 (62.3%)	295 (68.8%)	
Cisgender woman or girl	297 (30.9%)	185 (34.8%)	112 (26.1%)	0.0049*
TGNCNB[1]	37 (3.9%)	15 (2.8%)	22 (5.1%)	
Race/Ethnicity				
Asian/Pacific Islander	15 (1.6%)	0 (0.0%)	15 (3.5%)	
Black	548 (57.1%)	318 (59.9%)	230 (53.6%)	
Hispanic or Latino	329 (34.3%)	183 (34.5%)	146 (34.0%)	<0.0001*
Other or Mixed Race	18 (1.9%)	5 (0.9%)	13 (3.0%)	
White	49 (5.1%)	24 (4.5%)	25 (5.8%)	
Unknown	1 (0.1%)	1 (0.2%)	0 (0.0%)	
Borough of Residence				
Bronx	341 (35.5%)	244 (46.0%)	97 (22.6%)	
Brooklyn	320 (33.3%)	147 (27.7%)	173 (40.3%)	
Manhattan	154 (16.0%)	82 (15.4%)	72 (16.8%)	
Queens	95 (9.9%)	24 (4.5%)	71 (16.6%)	<0.0001*
Staten Island	29 (3.0%)	22 (4.1%)	7 (1.6%)	
Outside NYC but within NY EMA	7 (0.7%)	2 (0.4%)	5 (1.2%)	
Unknown	14 (1.5%)	10 (1.9%)	4 (0.9%)	
Primary Language				
English	741 (77.2%)	437 (82.3%)	304 (70.9%)	
Other	218 (22.7%)	94 (17.7%)	124 (28.9%)	<0.0001*
Unknown	1 (0.1%)	0 (0.0%)	1 (0.2%)	

Baseline characteristics of clients in the trial, by study arm

Characteristic	Total	Early Implementers (Phase 1)	Late Implementers (Phase 2)	p-value*
	N (%)	N (%)	N (%)	
	960 (100.0%)	531 (55.3%)	429 (44.7%)	
Country of Birth				
US/US territory	670 (69.8%)	433 (81.5%)	237 (55.2%)	<0.0001*
Other country	289 (30.2%)	98 (18.5%)	192 (44.8%)	
Transmission Risk				
MSM	321 (33.4%)	149 (28.1%)	172 (40.1%)	
IDU	50 (5.2%)	32 (6.0%)	18 (4.2%)	
MSM/IDU	8 (0.8%)	3 (0.6%)	5 (1.2%)	
Heterosexual	505 (52.6%)	298 (56.1%)	207 (48.3%)	0.0021*
Perinatal	52 (5.4%)	32 (6.0%)	20 (4.7%)	
Other/Unknown	24 (2.5%)	17 (3.2%)	7 (1.6%)	
Housing Status				
Stably housed	729 (75.9%)	378 (71.2%)	351 (81.8%)	0.0001*
Unstably housed or homeless	231 (24.1%)	153 (28.8%)	78 (18.2%)	
Incarceration History				
Never	707 (73.6%)	352 (66.3%)	355 (82.8%)	
Last 12 months	35 (3.6%)	25 (4.7%)	10 (2.3%)	<0.0001*
>12 months ago	208 (21.7%)	147 (27.7%)	61 (14.2%)	
Unknown	10 (1.0%)	7 (1.3%)	3 (0.7%)	
Sexual Orientation (self-reported)				
Gay or Lesbian	266 (27.7%)	125 (23.5%)	141 (32.9%)	
Straight or Heterosexual	579 (60.3%)	339 (63.8%)	240 (55.9%)	0.0048*
Bisexual	64 (6.7%)	33 (6.2%)	31 (7.2%)	
Other/Unknown[2]	51 (5.3%)	34 (6.4%)	17 (4.0%)	
Mental Health Diagnosis/Condition				
Yes	433 (45.1%)	286 (53.9%)	147 (34.3%)	
No	481 (50.1%)	222 (41.8%)	259 (60.4%)	<0.0001*
Unknown	46 (4.8%)	23 (4.3%)	23 (5.4%)	

Baseline characteristics of clients in the trial, by study arm

Characteristic	Total N (%) 960 (100.0%)	Early Implementers (Phase 1) N (%) 531 (55.3%)	Late Implementers (Phase 2) N (%) 429 (44.7%)	p-value*
Recent Hard Drug Use[3]				
Yes	183 (19.1%)	113 (21.3%)	70 (16.3%)	
No	761 (79.3%)	407 (76.6%)	354 (82.5%)	0.0718
Unknown	16 (1.7%)	11 (2.1%)	5 (1.2%)	
Lifetime Hard Drug Use[3]				
Yes	294 (30.6%)	178 (33.5%)	116 (27.0%)	
No	652 (67.9%)	343 (64.6%)	309 (72.0%)	0.0358*
Unknown	14 (1.5%)	10 (1.9%)	4 (0.9%)	
Insurance Status				
Insured	775 (80.7%)	476 (89.6%)	299 (69.7%)	<0.0001*
Uninsured	185 (19.3%)	55 (10.4%)	130 (30.3%)	
Employment Status				
Any paid employment	210 (21.9%)	76 (14.3%)	134 (31.2%)	
No paid employment	734 (76.5%)	451 (84.9%)	283 (66.0%)	<0.0001*
Unknown	16 (1.7%)	4 (0.8%)	12 (2.8%)	
Federal Poverty Level (FPL)				
<100% of FPL	780 (81.3%)	456 (85.9%)	324 (75.5%)	
100% - 200% of FPL	132 (13.8%)	54 (10.2%)	78 (18.2%)	0.0002*
>200% of FPL	47 (4.9%)	21 (4.0%)	27 (6.3%)	
Educational Level				
≤High school/GED or equivalent	700 (72.9%)	398 (75.0%)	302 (70.4%)	
>High school/GED	254 (26.5%)	130 (24.5%)	124 (28.9%)	0.2620
Unknown	6 (0.6%)	3 (0.6%)	3 (0.7%)	
Time Since Diagnosis				
≤1 year pre-enrollment	154 (16.0%)	51 (9.6%)	103 (24.0%)	
>1 – 10 years pre-enrollment	221 (23.0%)	111 (20.9%)	110 (25.6%)	
>10 – 20 years pre-enrollment	313 (32.6%)	199 (37.5%)	114 (26.6%)	<0.0001*
>20 years pre-enrollment	272 (28.3%)	170 (32.0%)	102 (23.8%)	

Baseline characteristics of clients in the trial, by study arm

Characteristic	Total	Early Implementers (Phase 1)	Late Implementers (Phase 2)	p-value*
	N (%)	N (%)	N (%)	
	960 (100.0%)	531 (55.3%)	429 (44.7%)	
Antiretroviral Therapy (ART) Status				
On ART	860 (89.6%)	479 (90.2%)	381 (88.8%)	0.4815
Not on ART	100 (10.4%)	52 (9.8%)	48 (11.2%)	
Viral Load (copies/mL)				
200 – 1,499	181 (18.9%)	101 (19.0%)	80 (18.6%)	
1,500 – 9,999	159 (16.6%)	85 (16.0%)	74 (17.2%)	0.3625
10,000+	603 (62.8%)	339 (63.8%)	264 (61.5%)	
No viral load at enrollment[4]	17 (1.8%)	6 (1.1%)	11 (2.6%)	
CD4 Count				
<200	422 (44.0%)	234 (44.1%)	188 (43.8%)	
200 – 499	352 (36.7%)	196 (36.9%)	156 (36.4%)	0.8283
500+	170 (17.7%)	94 (17.7%)	76 (17.7%)	
No CD4 at enrollment	16 (1.7%)	7 (1.3%)	9 (2.1%)	

Note: NYC = New York City; NY = New York; EMA = Eligible metropolitan area (for Ryan White HIV/AIDS Program Part A funding); MSM = Men who have sex with men; IDU = Injection drug users; GED = General Educational Development
[1]TGNCNB includes clients who identified their gender as transgender, gender nonconforming, non-binary, or not sure/questioning.
[2]Other includes clients who identified their sexual orientation as queer, pansexual, not sure/questioning, or other.
[3]Hard drug use refers to the use of cocaine/crack, heroin, crystal meth, or prescription drugs to get high.
[4]Eligible participants with no viral load test result at the time of their enrollment were classified as unsuppressed.
*Statistically significant (p<0.05)